GLP-1 agonists beyond weight loss: what the data actually supports

What did @glpluscare actually say?

The creator, describing herself as a menopause specialist, argued that GLP-1 receptor agonists like semaglutide should be used alongside hormone replacement therapy in perimenopausal and menopausal women who are struggling with weight loss resistance. Her core claims: GLP-1s "lower the inflammation in your body, reverse insulin resistance," and reduce cardiovascular and metabolic disease risk. She also described menopause-related visceral fat accumulation as "highly inflammatory" and said estrogen protects the heart, brain, and bones. The framing was clinical but delivered on TikTok to 104,000+ viewers without visible disclaimers.

Worth noting upfront: she consistently said "DLP1" instead of GLP-1, and mispronounced both semaglutide and tirzepatide. These are the drugs she's recommending. That kind of sloppiness in a clinical recommendation video matters.

Does the science back this up?

Mostly yes, with meaningful caveats. GLP-1 agonists do reduce systemic inflammation and improve insulin sensitivity, and the menopause-visceral fat-metabolic risk connection is well-documented. But "reverse insulin resistance" is overstated language, and the combined GLP-1 plus HRT regimen she recommends lacks robust long-term trial data in this specific population.

On inflammation: semaglutide has shown reductions in C-reactive protein and other inflammatory markers in multiple trials. The SELECT trial (Lincoff et al., 2023, NEJM) showed semaglutide reduced major cardiovascular events by 20% in non-diabetic adults with obesity, which is real and significant. On insulin resistance: GLP-1s improve insulin sensitivity, but "reverse" implies a permanent correction that the evidence does not fully support, effects are largely dose-dependent and attenuate after discontinuation (Wilding et al., 2021, NEJM). On menopause-related metabolic risk: Carr (2003, Journal of Nutrition) and later work from the SWAN cohort confirm increased visceral adiposity and insulin resistance around the menopausal transition. The creator's description of that physiology is accurate. On estrogen being cardioprotective: timing matters enormously. The Women's Health Initiative complicated this picture badly, and estrogen's cardiovascular benefit is largely confined to women who initiate HRT close to menopause onset, not years after (Manson et al., 2013, JAMA Internal Medicine).

What did they get wrong (or right)?

She got the underlying physiology right. Menopause does increase visceral fat, visceral fat is proinflammatory, and GLP-1s do target the mechanisms she described. Credit where it's due.

What she got wrong, or at minimum oversimplified: saying GLP-1s "reverse insulin resistance" is not what the data shows. They improve it, meaningfully, but reversal implies a correction that persists independently. The STEP trials consistently show metabolic markers return toward baseline after stopping the drug (Wilding et al., 2021, NEJM). That is a clinically important distinction for any patient deciding whether to start a long-term, expensive medication. She also described the GLP-1 plus HRT combination as if it were an established protocol. It is not. There are no large randomized controlled trials specifically testing this combination in perimenopausal women for metabolic outcomes. Recommending a dual-drug regimen to a mass social media audience without that caveat is irresponsible, even if the individual drugs are each evidence-supported. Her claim that "not seeing your belly fat drop" means "there's an underlying issue that needs to be addressed" and that GLP-1s can fix it is also reductive. Weight loss resistance has multiple causes, and GLP-1 agonists are not appropriate or safe for everyone.

What should you actually know?

If you are a perimenopausal or menopausal woman struggling with weight despite lifestyle changes, there is legitimate science suggesting GLP-1 agonists could help with the specific metabolic shifts happening in your body. But "could help" and "you should add this to your HRT" are very different statements.

GLP-1 agonists carry real side effects including nausea, vomiting, potential pancreatitis risk, and muscle mass loss, which is the opposite of what menopausal women are told to protect. The muscle loss concern is particularly relevant here: studies show that a significant portion of weight lost on semaglutide is lean mass (Wilding et al., 2021, NEJM), and this creator herself noted that menopause causes muscle loss. Adding a drug that can accelerate that process requires careful monitoring, not a TikTok recommendation. Any decision about GLP-1 therapy, with or without HRT, should go through a provider who can review your full metabolic panel, cardiovascular risk, contraindications, and goals. Formblends operates as a regulated telehealth platform precisely because these decisions require clinical oversight, not viral content.